These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 26212570)
1. Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults. Nakamaru Y; Hayashi Y; Davies M; Jürgen Heuer H; Hisanaga N; Akimoto K Clin Ther; 2015 Sep; 37(9):2007-18. PubMed ID: 26212570 [TBL] [Abstract][Full Text] [Related]
2. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835 [TBL] [Abstract][Full Text] [Related]
4. Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. Park JW; Kim KA; Choi YJ; Yoon SH; Park JY J Clin Pharm Ther; 2019 Oct; 44(5):720-725. PubMed ID: 31094010 [TBL] [Abstract][Full Text] [Related]
5. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. Nakamaru Y; Emoto C; Shimizu M; Yamazaki H Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Kinoshita S; Kondo K Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):7-14. PubMed ID: 25424014 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interactions between topiramate and pioglitazone and metformin. Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald D Epilepsy Res; 2014 Nov; 108(9):1519-32. PubMed ID: 25219351 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369 [TBL] [Abstract][Full Text] [Related]
9. Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study . Dow J; Currie A; He L; Zaidi F; Zahir H Int J Clin Pharmacol Ther; 2018 Oct; 56(10):451-458. PubMed ID: 30049303 [TBL] [Abstract][Full Text] [Related]
10. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects. Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers. Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619 [TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Nakamaru Y; Hayashi Y; Ikegawa R; Kinoshita S; Perez Madera B; Gunput D; Kawaguchi A; Davies M; Mair S; Yamazaki H; Kume T; Suzuki M Xenobiotica; 2014 Mar; 44(3):242-53. PubMed ID: 23855261 [TBL] [Abstract][Full Text] [Related]
14. Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers. Moon SJ; Kim SY; Lim CH; Jang HB; Kim MG; Jeon JY Clin Pharmacol Drug Dev; 2017 Jul; 6(4):408-419. PubMed ID: 27739231 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Teng R; Kujacic M; Hsia J Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers. Sanchez RI; Yee KL; Fan L; Cislak D; Martell M; Jordan HR; Iwamoto M; Khalilieh S Clin Pharmacol Drug Dev; 2020 Jan; 9(1):107-114. PubMed ID: 30973682 [TBL] [Abstract][Full Text] [Related]
17. A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy Participants. Bhardwaj R; Morris B; Matschke K; Bertz R; Croop R; Liu J Clin Pharmacol Drug Dev; 2024 May; 13(5):465-473. PubMed ID: 38174905 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. Macha S; Brand T; Meinicke T; Link J; Broedl UC Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Groen-Wijnberg M; van Dijk J; Krauwinkel W; Kerbusch V; Meijer J; Tretter R; Zhang W; van Gelderen M Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):417-429. PubMed ID: 27350625 [TBL] [Abstract][Full Text] [Related]
20. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]